SELLAS Life Sciences Group (NASDAQ:SLS) Sees Strong Trading Volume – Time to Buy?

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw an uptick in trading volume on Tuesday . Approximately 6,253,825 shares changed hands during mid-day trading, a decline of 25% from the previous session’s volume of 8,341,135 shares.The stock last traded at $14.1320 and had previously closed at $15.45.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Maxim Group raised their price target on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.

SELLAS Life Sciences Group Trading Down 10.1%

The stock has a market cap of $2.61 billion, a P/E ratio of -57.70 and a beta of 2.41. The company’s fifty day simple moving average is $7.71 and its 200-day simple moving average is $5.44.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Larson Financial Group LLC bought a new position in SELLAS Life Sciences Group in the 4th quarter valued at $26,000. California State Teachers Retirement System grew its position in shares of SELLAS Life Sciences Group by 22.4% during the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after buying an additional 1,709 shares during the period. Beacon Pointe Advisors LLC acquired a new stake in SELLAS Life Sciences Group during the 4th quarter worth $38,000. Concurrent Investment Advisors LLC acquired a new stake in shares of SELLAS Life Sciences Group during the fourth quarter worth $38,000. Finally, Money Concepts Capital Corp bought a new stake in shares of SELLAS Life Sciences Group in the 4th quarter valued at about $40,000. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.